Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation
; 148(8): 651-660, 2023 08 22.
Article
in En
| MEDLINE
| ID: mdl-37603600
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Diabetic Nephropathies
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Year:
2023
Type:
Article